Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IOV-3001 · 1 trial · 3 indications
The frequency and severity of treatment emergent adverse events and serious adverse events will be assessed when IOV-3001 administered
Determine the recommended dose for Phase 2
| Arm | Type | Description |
|---|---|---|
| Assigned Interventions | EXPERIMENTAL | Dose escalation participants with unresectable or metastatic melanoma |
| Name | Type | Description |
|---|---|---|
| IOV-3001 | BIOLOGICAL | IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting. |
Inclusion Criteria: 1. Participant must be ≥ 18 years of age at the time of signing the informed consent. 2. Participant has unresectable or metastatic melanoma. 3. Participant has melanoma not of uveal/ocular origin and experienced documented radiographic disease progression during systemic therap...
IOV-3001 is an investigational monoclonal antibody being developed for the treatment of unresectable melanoma, including metastatic melanoma and ocular melanoma. It is currently being studied in a Phase 1 clinical trial in adults with advanced melanoma who will also receive lifileucel.
IOV-3001 targets the IL-2 receptor (IL-2R), a receptor involved in immune cell signaling. By binding to IL-2R, the antibody is designed to modulate immune responses, which may be relevant in the context of cancer treatment for melanoma.
IOV-3001 is being developed by Iovance Biotherapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IOVA. The company is conducting clinical research on this investigational therapy for melanoma.
IOV-3001 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate its safety and efficacy.
IOV-3001 is being studied in a single Phase 1 clinical trial with the identifier NCT06940739. This trial is recruiting adults with advanced melanoma, including unresectable, metastatic, and ocular melanoma, and is being conducted in the United States and Australia.
No, IOV-3001 is not the same as lifileucel. IOV-3001 is a monoclonal antibody targeting IL-2R, while lifileucel is a separate therapy. In the clinical trial, patients receive IOV-3001 in combination with lifileucel, but they are distinct investigational agents.